SU806037A1 - Antianginal agent - Google Patents
Antianginal agent Download PDFInfo
- Publication number
- SU806037A1 SU806037A1 SU782605039A SU2605039A SU806037A1 SU 806037 A1 SU806037 A1 SU 806037A1 SU 782605039 A SU782605039 A SU 782605039A SU 2605039 A SU2605039 A SU 2605039A SU 806037 A1 SU806037 A1 SU 806037A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- effect
- antianginal
- nitroglycerin
- water
- acrylamide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Abstract
Description
(54) АНТИАНГИНАЛЬНОЕ СРЕДСТВО(54) ANTIANGINAL MEANS
Изобретение относитс к медицине, а именно фармации, к лекарственным средствам, используемым в кардиологии дл лечени коронарной недостаточности. В медицинской практике известно применение в качестве антиангинального средства нитроглицерина дл лечени приступов стенокардни Ц. Однако известное антиангинальное средство обладает побочным эффектом и кратковременным действием. Цель изобретени - снижение побочного дей стви и пролонгирование действи антиангиналь ного средства. Поставленна цель достигаетс тем, что в со став антиангинального средства дл снижени побочного действи в качестве водорастворимого носител введены гомополимеры акриламида N-винилпирролидона или их сополимеры с акрклатами при следующем количественном соотношении компонентов, вес. %: Антиангинальное средство на основе преимущественно ннтро глицерина3-30 Водорастворимый носитель70-97 А с целью пролонгировани действи оно дополнительно содержит дисперсии твердых жиров с температурой плавлени 30-50° С от 3 до 30 вес. % сверх 100%. Антиангннальные средства получают, использу известные технологические операции - лекарственный препгфат и водорастворимый носитель раствор ют в растворител х, совмещающихс друг с дфугом или в общем растворителе , смешивают растворы, обеспечива необходимое соошошение компонентов, отливают luioiKH толццгаой 0,1-1,0 мм на инертных подложках , сушат пленки при температуре до 40°С до остаточного содержани растворител не более 10%, после чего формуют пластинки заданного размера, обеспечива разовую дозу препарата. Дл обеспечени пролонгированного действи перед отливом пленок в смесь растворов препаратов и водорастворимого носител ввод т дисперсию жира в том же растворителе , обеспечива требуемое его содержание в составе антиангинального средства. Пример. Приготавливают композицию лекарственного средства следующего состава , %: Нитроглицерин3 Полиакриламид (молекул рна масса 700000) Компоненты последовательно раствор ют в дистиллированной воде, ползша растворы 10-20%-ной концентра щи. Из растворов отли вают пленки любым известным способом (по вом на инертную подложку, напылением, осаж дением в электростатическом поле и т.д.) из которых вырубают пластинки желаемой форм и размеров, обеспечива необходимую дозиро ку лекарственного препарата. Пример. Приготавливают композицию лекарственного средства следующего сост ва, %: Нитроглицерин 30 Сополимер акриламида, N-винилпирролидона и зтилакрилата (соотнощение 1:1:1; молекул рна масса 80 000) 70 Компоненты последовательно раствор ют в водно-спиртовой смеси при соотнощении во да:спирт 75:25, получа растворы 10-20%-ной концентрации. Далее, как описано в примере П р и м е р 3. Приготавливают композицию лекарственного средства следующего состава , %: Нитроглицерин10 Сополимер акриламида, N-винилпирролидона и бутилакрилата (соотнощение 1:0,5:0,3; молекул рна масса 80 000)90 Компоненты последовательно раствор ют в водно-спиртовой смеси при соотнощении вода спирт 75:25, получа растворы 10-20%-ной концентрации. Далее, как описано в примере П р и м е р 4. Приготавливают композиц лeк ctвeннoгo средства следующего состава, Нитроглицерин3 Сополимер акриламида, N-вшшлпирролидона и этилакрилата (соотнощение 0,6:0,2:0,2; молекул рна масса 50 000)97 Масло какао3 ( сверх 100) Компоненты последовательно раствор ют и диспергируют в водно-спиртовом растворе пр соотношенни вода:сшфт 75:25, получа раств {ш дисперсии 10-20%-ной концентрации . Дл диспергировани могут использоватьс любые известные способы (механическое перемещив , ультразвукова обработка и др.). Далее, описано в примере 1. П р и м е р 5. Приготавливают композилекарственного средства следующего сова , %: Нитроглицерин5 Сополимер акриламида, N- винилпирролидона и этилакрилата (соотнощение 0,6:0,2:0,2; молекул рна масса 500 000)95 Масло какао 30 ( сверх 100) Далее, как описано в примере 4. Пример 6. Приготавливают композилекарственного средства следующего соа , %: Нитроглицерин5 Сополимер акриламида, N-винилпирролидона и этилакрилата (соотнощение 0,6:0,2:0,2; молекул рна масса 500 000)95 Гидрогенизировашюе хлопковое масло .10 ( сверх 100) Далее, как описано в примере 4. П р И М е р 7. Приготавливают композилекарственного средства следующего соста%: Пентаэритриттетранитрат20 Сополимер акриламида, М-винилпирролидона и зтилакрилата (соотнощение 0,6:0,2:0,2; молекул рна 80 масса 500 000)ю Масло какао(сверх 100) Далее, как описано в примере 4. ПримерЗ. Приготавливают композилекарственного средства следующего сова , %: Нитроглицерин5 Сополимер акриламида, N-виншпгарролидона и этилакрилата (соотнощение 0,6:0,2:0,2; молекул рна масса 500 000)95 Гищюгениз1фоваш1ый ланолин10 ( сверх 100) Далее, как описано в примере 4. П р н м е р 9. Приготавливают композилекарственного средства следующего сова , %: Изосорбитдишлграт20 ( шгтросорбит) Сополимер акриламида, N-винилпирролидона и этилакрилата (соотнощение 0,6:0,2:0,2; молекул рна масса 500 000) Компоненты последовательно раствор ют в водно-спиртовой смеси при соотношении вода спирт 50:50, получа растворы 15-20%-ной концентрации. Далее, как описано в примере 1. В отличие от известных полимерные носители указанной природы при контакте с водными растворами обеспечивают более равноме ное выделение лекарственного препарата, что снижает и устран ет побочные эффекты в виде головных болей или резкого изменени кр в ного давлени , наблюдаемые при приеме, известных антиангинальных средств.The invention relates to medicine, namely pharmacy, to drugs used in cardiology for the treatment of coronary insufficiency. In medical practice, it is known to use nitroglycerin as an antianginal agent for treating strokes of angina C. However, the known antianginal agent has a side effect and a short-term effect. The purpose of the invention is to reduce the side effects and prolong the action of the antianginal agent. The goal is achieved by the fact that homopolymers of acrylamide N-vinylpyrrolidone or their copolymers with acrylates are introduced into the composition of an antianginal agent to reduce the side effects as a water-soluble carrier with the following quantitative ratio of the components, wt. %: Antianginal agent based on predominantly ntro glycerol3-30 Water-soluble carrier 70-97 A for the purpose of prolonging its action, it additionally contains dispersions of solid fats with a melting point of 30-50 ° C from 3 to 30 wt. % over 100%. Anti-angnostic agents are obtained using known technological procedures — the medicinal prepgfat and the water-soluble carrier are dissolved in solvents that are combined with each other or in a common solvent; the solutions are mixed, providing the necessary alignment of the components, cast with 0.1-1.0 mm thick on inert luioiKH the substrates, the films are dried at a temperature up to 40 ° C to a residual solvent content of not more than 10%, after which plates of a given size are formed, providing a single dose of the preparation. To ensure prolonged action, before the films are cast, a dispersion of fat in the same solvent is introduced into the mixture of the solutions of the preparations and the water-soluble carrier, ensuring the required content of the antianginal agent. Example. A drug composition of the following composition is prepared,%: Nitroglycerin3 Polyacrylamide (molecular weight 700,000) The components are successively dissolved in distilled water, crawling solutions of 10–20% concentration of shchi. Films are poured from solutions by any known method (on an inert substrate, sputtering, deposition in an electrostatic field, etc.) from which plates of the desired shape and size are cut down, providing the necessary dosage of the drug. Example. A drug composition of the following composition is prepared,%: Nitroglycerin 30 Acrylamide, N-vinylpyrrolidone and ethyl acrylate copolymer (ratio 1: 1: 1; molecular weight 80,000) 70 The components are successively dissolved in an aqueous-alcohol mixture at a ratio of: alcohol 75:25, obtaining solutions of 10–20% concentration. Further, as described in example EXAMPLE 3. A composition of a medicinal product of the following composition is prepared,%: Nitroglycerin10 Acrylamide, N-vinylpyrrolidone and butyl acrylate copolymer (ratio 1: 0.5: 0.3; molecular weight 80,000) 90 The components are sequentially dissolved in a water-alcohol mixture at a ratio of water to alcohol 75:25, yielding solutions of 10–20% concentration. Further, as described in Example EXAMPLE 4. Prepare a Composition of Lacquers of Equivalent Agents of the Following Composition, Nitroglycerin 3 Acrylamide, N-Svirpyrrolidone and ethyl acrylate copolymer (0.6: 0.2: 0.2; molecular weight 50,000 ) 97 Cocoa butter 3 (over 100) The components are sequentially dissolved and dispersed in a water-alcohol solution at a ratio of water: cotton 75:25, obtaining a solution {w dispersion of 10–20% concentration. For dispersion, any known methods can be used (mechanical displacement, ultrasonic treatment, etc.). Further, it is described in Example 1. EXAMPLE 5. Composite drugs are prepared following owl,%: Nitroglycerin 5 Acrylamide, N-vinylpyrrolidone and ethyl acrylate copolymer (ratio 0.6: 0.2: 0.2; molecular weight 500 000) 95 Cocoa Butter 30 (in excess of 100) Further, as described in Example 4. Example 6. Prepare a composite drug of the following coa,%: Nitroglycerin 5 Acrylamide, N-vinylpyrrolidone and ethyl acrylate copolymer (ratio of 0.6: 0.2: 0, 2; molecular weight 500,000) 95 Hydrogenated cottonseed oil .10 (over 100) Further, as described in approx. 4. Compositing drugs of the following composition are prepared: Pentaerythritol tetranitrate20 Acrylamide copolymer, M-vinylpyrrolidone and ethyl acrylate (ratio 0.6: 0.2: 0.2; molecular weight 80,000,000) o Oil cocoa (over 100) Further, as described in example 4. Example3. Composite the following owl is prepared,%: Nitroglycerin5 Acrylamide, N-vinsphgarrolidone and ethyl acrylate copolymer (ratio 0.6: 0.2: 0.2; molecular weight 500,000) 95 Gysthygenizene lanolin 10 (over 100) Next, as described in example 4. Example 9. Composites are prepared with the following owl,%: Isosorbittistilgrat20 (schtrosorbit) Acrylamide, N-vinylpyrrolidone and ethyl acrylate copolymer (ratio 0.6: 0.2: 0.2; molecular weight 500,000) The components are sequentially dissolved in a water-alcohol mixture at a ratio of Water alcohol 50:50, obtaining solutions of 15-20% concentration. Further, as described in Example 1. In contrast to the known polymeric carriers of the indicated nature, upon contact with aqueous solutions, they provide a more even release of the drug, which reduces and eliminates side effects in the form of headaches or drastic changes in the crush pressure. admission, known antianginal drugs.
Гранулы с сахаром 40 70 100Granules with sugar 40 70 100
Пленки на основе Based films
20 35 полиакрил амида20 35 polyacryl amide
Claims (2)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU782605039A SU806037A1 (en) | 1978-04-06 | 1978-04-06 | Antianginal agent |
CA324,996A CA1127082A (en) | 1978-04-06 | 1979-04-05 | Antianginal film and method of treating ischemic heart disease |
DE19792913752 DE2913752A1 (en) | 1978-04-06 | 1979-04-05 | MEDICINAL FILM WITH ANTIANGINAL EFFECT |
GB7912104A GB2021610B (en) | 1978-04-06 | 1979-04-06 | Antianginal composition |
JP54041172A JPS6024763B2 (en) | 1978-04-06 | 1979-04-06 | anti-angina film |
GB8120761A GB2078771B (en) | 1978-04-06 | 1979-04-06 | Drug carrier |
FR7908827A FR2421610A1 (en) | 1978-04-06 | 1979-04-06 | MEDICINAL FILM BASED ON AN ACTIVE SUBSTANCE WITH ANTI ANGINOUS ACTION SUCH AS NITROGLYCERIN OR ISOSORBIDE DIMITRATE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU782605039A SU806037A1 (en) | 1978-04-06 | 1978-04-06 | Antianginal agent |
Publications (1)
Publication Number | Publication Date |
---|---|
SU806037A1 true SU806037A1 (en) | 1981-02-23 |
Family
ID=20759951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU782605039A SU806037A1 (en) | 1978-04-06 | 1978-04-06 | Antianginal agent |
Country Status (6)
Country | Link |
---|---|
JP (1) | JPS6024763B2 (en) |
CA (1) | CA1127082A (en) |
DE (1) | DE2913752A1 (en) |
FR (1) | FR2421610A1 (en) |
GB (2) | GB2021610B (en) |
SU (1) | SU806037A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4529589A (en) * | 1981-07-14 | 1985-07-16 | Davydov Anatoly B | Pharmaceutical composition for the treatment of diabetes mellitus |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4291015A (en) * | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
IL61721A (en) * | 1980-12-16 | 1984-03-30 | Blank Izhak | Nitroglycerin preparations |
JPS57116011A (en) * | 1981-01-08 | 1982-07-19 | Nitto Electric Ind Co Ltd | Pharmaceutical preparation |
CA1218604A (en) * | 1981-07-08 | 1987-03-03 | Alec D. Keith | Trinitroglycerol sustained release vehicles and preparations therefrom |
AU553343B2 (en) * | 1981-08-10 | 1986-07-10 | Advance Electrode Kabushikikaisya | Absorbent adhesive bandage with medicament release |
US4482533A (en) * | 1982-01-11 | 1984-11-13 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing propranolol |
ZA836627B (en) * | 1982-10-08 | 1984-05-30 | Verex Lab | Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility |
FR2542998B1 (en) * | 1983-03-24 | 1986-01-31 | Rhone Poulenc Sante | NEW TRANSDERMAL FORM OF ISOSORBIDE DINITRATE |
US4693887A (en) * | 1983-09-15 | 1987-09-15 | The Kendall Company | Microphase separated hydrogels for controlled release of bioactive materials |
JPS6066759A (en) * | 1983-09-21 | 1985-04-16 | 日東電工株式会社 | Pharmaceutical preparation |
JPS60148471A (en) * | 1983-12-27 | 1985-08-05 | マンヴイル サービス コーポレーション | Crown support type carrier |
US5364628A (en) * | 1985-05-31 | 1994-11-15 | Sandoz Ltd. | Pharmaceutical compositions |
JPS61280423A (en) * | 1985-06-05 | 1986-12-11 | Kiyuukiyuu Yakuhin Kogyo Kk | Mucosal application agent in oral cavity |
US4764378A (en) * | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
DE3823395A1 (en) * | 1988-07-09 | 1990-03-15 | Holzapfel Boeving Partner Werb | Cloth impregnated with an active substance |
US5232703A (en) * | 1989-07-21 | 1993-08-03 | Izhak Blank | Estradiol compositions and methods for topical application |
DE69007886T2 (en) * | 1989-07-21 | 1994-11-17 | Izhak Blank | Oestradiol containing agents and methods for topical use. |
US5204109A (en) * | 1989-12-28 | 1993-04-20 | Nitto Denko Corporation | Percutaneous gel preparation |
US9023382B2 (en) | 2005-06-08 | 2015-05-05 | Basf Corporation | Medicament carrier composition and method of forming a film therefrom |
EP2887927B1 (en) * | 2012-08-23 | 2018-03-28 | Cardiolynx AG | Extended release compositions of an amino-c2-c6-alkyl nitrate |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE859931C (en) * | 1944-05-24 | 1952-12-18 | Roehm & Haas G M B H | Galenic preparations |
DE2301664C3 (en) * | 1973-01-13 | 1979-07-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Oral medicine containing nitroglycerin |
JPS5138412A (en) * | 1974-09-24 | 1976-03-31 | Nippon Kayaku Kk | Kokoseizai no seiho |
GB1568837A (en) * | 1975-10-10 | 1980-06-04 | Squibb & Sons Inc | Controlled release tablet |
DE2634004B2 (en) * | 1976-07-29 | 1978-08-10 | Bernhard Dr. 8000 Muenchen Lippold | Process for accelerating the dissolution and improving the solubility of poorly soluble drugs intended for oral administration |
-
1978
- 1978-04-06 SU SU782605039A patent/SU806037A1/en active
-
1979
- 1979-04-05 DE DE19792913752 patent/DE2913752A1/en not_active Ceased
- 1979-04-05 CA CA324,996A patent/CA1127082A/en not_active Expired
- 1979-04-06 JP JP54041172A patent/JPS6024763B2/en not_active Expired
- 1979-04-06 FR FR7908827A patent/FR2421610A1/en active Granted
- 1979-04-06 GB GB7912104A patent/GB2021610B/en not_active Expired
- 1979-04-06 GB GB8120761A patent/GB2078771B/en not_active Expired
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4529589A (en) * | 1981-07-14 | 1985-07-16 | Davydov Anatoly B | Pharmaceutical composition for the treatment of diabetes mellitus |
Also Published As
Publication number | Publication date |
---|---|
FR2421610B1 (en) | 1982-11-12 |
JPS6024763B2 (en) | 1985-06-14 |
JPS54154511A (en) | 1979-12-05 |
GB2021610B (en) | 1982-10-20 |
FR2421610A1 (en) | 1979-11-02 |
GB2078771A (en) | 1982-01-13 |
GB2021610A (en) | 1979-12-05 |
GB2078771B (en) | 1983-03-09 |
DE2913752A1 (en) | 1979-12-20 |
CA1127082A (en) | 1982-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU806037A1 (en) | Antianginal agent | |
US4294820A (en) | Polymeric diffusion matrix containing phenylephrine | |
CA2330500A1 (en) | Pharmaceutical compositions capable of being gelled | |
BE901994A (en) | TABLETS OF FAST DELITTING PHARMACEUTICAL ACTIVE INGREDIENTS, STABLE ON STORAGE. | |
NO934523D0 (en) | Procedure for adjusting the saturation concentration of a drug for transdermal administration | |
FR2643556A1 (en) | PHARMACEUTICAL COMPOSITION WITH SUSTAINED RELEASE OF VALPROIC ACID | |
GEP20002211B (en) | Taxoids, Preparation Thereof, Pharmaceutical Compositions Containing Same | |
RU94035739A (en) | Pharmaceutical composition containing nifedipin and method of its preparing | |
US8003696B2 (en) | Composition and method for treating bacterial, viral, fungal diseases, inflammation and pain | |
FR2464714A1 (en) | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING TRIETHYLENETETRAMINE | |
JPS6242973A (en) | L-lisine pyruvate and l-histidine pyruvate | |
KR960704911A (en) | 2 ', 5'-oligoadenylate-2', 3'-cyclophosphate (2 ', 5'-OLIGOADENYLATE-2', 3'-CYCLOPHOSPHATES) | |
FR2676363A1 (en) | PROPHYLACTIC ANTIDOTE AGAINST ORGANOPHOSPHORIC PISCES. | |
US4857313A (en) | Transdermal drug delivery device comprising copolymers of N-morpholinoethyl methacrylate and 2-hydroxylmethacrylate | |
EP2910254B1 (en) | Base and external preparation for skin | |
JPS635378B2 (en) | ||
CA2259584A1 (en) | Plasters containing isosorbide dinitrate | |
FR2522968A1 (en) | CYTOTOXIC DRUG FORM OF THE ASSOCIATION OF AT LEAST ONE IMMUNOTOXIN AND CHLOROQUIN | |
US4006223A (en) | Drug composition intended for the treatment of acute, lethal and chronic radiation disease | |
FR2536997A1 (en) | CYTOTOXIC DRUGS COMPRISING AT LEAST ONE IMMUNOTOXIN AND METHYLAMINE | |
RU95105249A (en) | Ng monomethyl-l-arginine hydrochloride, processes for preparation thereof, process for preparation of pharmaceutical agent, and method of treatment | |
FR2584604A1 (en) | Therapeutic composition constituting a new oral pharmaceutical dosage form for improving the kinetics of bioavailability | |
CH684521A5 (en) | A therapeutic composition comprising a complex of polyadenylic acid with polyuridylic acid. | |
RU2007164C1 (en) | Process for preparing drug having antitumor, antifungal and antiviral activity | |
KR100334372B1 (en) | Percutaneous medications to suppress unwanted analgesic, inhibit premature birth, and control analgesic |